Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)-Reference-Cited by-同舟云学术

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

Published:2016-07 Issue:1 Volume:70 Page:136-145
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Drake Marcus J.,Chapple Christopher,Esen Ahmet A.,Athanasiou Stavros,Cambronero Javier,Mitcheson David,Herschorn Sender,Saleem Tahir,Huang Moses,Siddiqui Emad,Stölzel Matthias,Herholdt Claire,MacDiarmid Scott

Publisher

Elsevier BV

Subject

Urology

Reference32 articles.

1. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society;Abrams;Neurourol Urodyn,2002

2. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013;Drake;Neurourol Urodyn,2014

3. Defining overactive bladder: epidemiology and burden of disease;Tubaro;Urology,2004

4. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review;Bartoli;Urology,2010

5. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder;Tang;BJU Int,2014

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The history of the pharmacologic treatment of urgency incontinence;Continence Reports;2024-09

2. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials;Frontiers in Surgery;2024-08-26

3. Management of overactive bladder: consensus statements from the Hong Kong Urological Association and the Hong Kong Geriatrics Society;Hong Kong Medical Journal;2024-08-14

4. Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update;Expert Opinion on Emerging Drugs;2024-06-14

5. Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study;European Urology Focus;2024-03